Current filters:

Emergent BioSolutions

1 to 9 of 10 results

Emergent BioSolutions and MorphoSys to co-develop prostate cancer drug candidate ES414

Emergent BioSolutions and MorphoSys to co-develop prostate cancer drug candidate ES414


US biopharmaceutical firm Emergent BioSolutions and Germany’s MorphoSys have entered into an agreement…

BiotechnologyEmergent BioSolutionsES414GermanyLicensingMOR209/ES414MorphoSysOncologyProstate cancerUSA

Valneva deal with Emergent BioSolutions for development of vaccines in the EB66 cell line


European biotechnology company Valneva has signed a new research license agreement and transferred an…

BiotechnologyEB66 cell lineEmergent BioSolutionsLicensingVaccinesValneva

Emergent BioSolutions to acquire Cangene for $222 million


Taking a significant step to solidify its leadership position in the growing biodefense market, US vaccine…

CangeneEmergent BioSolutionsMergers & AcquisitionsNorth AmericaPharmaceuticalVaccines

Emergent BioSolutions gets exclusive US commercial rights to pandemic flu vaccine candidate


US vaccine maker Emergent BioSolutions (NYSE: EBS) has signed a license agreement with fellow USA-based…

BiotechnologyEmergent BioSolutionsLicensingNorth AmericaVaccinesVaxInnate Corp

Emergent considers options as Abbott ends drug R&D collaboration


Shares of USA-based Emergent BioSolutions (NYSE: EBS) saw its shares fall 4% to $16.53 after the company…

Abbott LaboratoriesEmergent BioSolutionsLicensingOncologyPharmaceuticalResearch

Emergent BioSolutions gets $1.25 billion BioThrax order for US government


Emergent BioSolutions (NYSE: EBS) revealed yesterday that it has received an award to supply the US government…

BioThraxEmergent BioSolutionsFinancialMarkets & MarketingNorth AmericaPharmaceuticalVaccines

Emergent BioSolutions gets late-stage MAb cancer therapy from TenX BioPharma


Emergent BioSolutions (NYSE: EBS) has acquired from fellow USA-based TenX BioPharma the rights to zanolimumab,…

BiotechnologyEmergent BioSolutionsLicensingOncologyPharmaceuticalTenX BioPharmazanolimumab

Oxford BioMedica licences Hi-8 PrimeBoost vaccines technology to Emergent BioSolutions in $20 million accord


UK-based gene therapy firm Oxford BioMedica has signed a licensing deal with Emergent Product Development…

BiotechnologyEmergent BioSolutionsLicensingOxford BioMedicaPharmaceuticalRespiratory and PulmonaryVaccines

1 to 9 of 10 results



Back to top